330 related articles for article (PubMed ID: 26749374)
1. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.
Mise N; Takami M; Suzuki A; Kamata T; Harada K; Hishiki T; Saito T; Terui K; Mitsunaga T; Nakata M; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S
Cancer Sci; 2016 Mar; 107(3):233-41. PubMed ID: 26749374
[TBL] [Abstract][Full Text] [Related]
2. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
3. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
4. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
5. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
[TBL] [Abstract][Full Text] [Related]
6. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Mol BM; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Cancer Lett; 2008 Dec; 272(1):70-6. PubMed ID: 18684557
[TBL] [Abstract][Full Text] [Related]
8. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
9. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
10. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Yang G; Artiaga BL; Lewis ST; Driver JP
Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
[TBL] [Abstract][Full Text] [Related]
11. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
12. Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.
Andrews K; Hamers AAJ; Sun X; Neale G; Verbist K; Tedrick P; Nichols KE; Pereira S; Geraghty DE; Pillai AB
Cytotherapy; 2020 May; 22(5):276-290. PubMed ID: 32238299
[TBL] [Abstract][Full Text] [Related]
13. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
[TBL] [Abstract][Full Text] [Related]
15. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
16. Decreased invariant natural killer T-cell-mediated antitumor immune response in patients with gastric cancer.
Ascui G; Gálvez-Jirón F; Kramm K; Schäfer C; Siña J; Pola V; Cristi F; Hernández C; Garrido-Tapia M; Pesce B; Bustamante M; Fluxá P; Molina MC; Ribeiro CH
Immunol Cell Biol; 2020 Jul; 98(6):500-513. PubMed ID: 32189398
[TBL] [Abstract][Full Text] [Related]
17. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
18. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
[TBL] [Abstract][Full Text] [Related]
19. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]